<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04852731</url>
  </required_header>
  <id_info>
    <org_study_id>2020-A02680-39</org_study_id>
    <nct_id>NCT04852731</nct_id>
  </id_info>
  <brief_title>STretch and Myocardial Characterization in Arrythmogenic Mitral Valve Prolapse-2</brief_title>
  <acronym>STAMP-2</acronym>
  <official_title>Dynamic Evaluation of Myocardial Fibrosis and Structural Determinants of Ventricular Arrhythmia in Mitral Valve Prolapse (STAMP-2 : STretch and Myocardial Characterization in Arrythmogenic Mitral Valve Prolapse-2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mitral valve prolapse (MVP) is a frequent affection of the mitral valve with a prevalence of&#xD;
      2-3% in the general population. This valvular disease is generally considered as benign, but&#xD;
      may at term evolve toward mitral valve regurgitation of various severity and/or arrhythmia.&#xD;
&#xD;
      Mitral valve prolapse is routinely diagnosed using transthoracic echocardiography. Subsequent&#xD;
      examinations (24-hour external loop recording, exercise electrocardiogram, cardiac Magnetic&#xD;
      Resonance Imaging) and a close follow-up can be proposed to the patient depending on its&#xD;
      condition.&#xD;
&#xD;
      More recently, detection of myocardial fibrosis and a mitral ring disjunction among patients&#xD;
      with MVP were associated with the occurrence of severe ventricular arrhythmia.&#xD;
&#xD;
      The investigators hypothesize that ventricular remodeling over time is mediated by the&#xD;
      progression of mitral insufficiency severity from myocardial fibrosis secondary to MVP and&#xD;
      possibly promoted by other mitral valve abnormalities. This remodeling, characterized by&#xD;
      circulating biomarkers and imaging (MRI and echocardiography), could allow the identification&#xD;
      of patients with a higher risk of severe ventricular arrhythmia.&#xD;
&#xD;
      The main objective of this study is to identify prognostic factors for unfavorable evolution&#xD;
      (ventricular remodeling or a rhythm disorder event) at 3 years from initial assessments in&#xD;
      MVP patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2027</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2027</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of ventricular remodelling</measure>
    <time_frame>3 years</time_frame>
    <description>Variation of at least 10% of the telestolic volume observed at 3 years on cardiac MRI compared to the initial cardiac MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence of ventricular arrythmia (fibrillation or tachycardia, extrasystoles)</measure>
    <time_frame>3 years</time_frame>
    <description>Occurrence of any ventricular arrythmia on external loop recording or exercise ECG</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Mitral Valve Prolapse</condition>
  <arm_group>
    <arm_group_label>Group A (a) : patients without mitral regurgitation without ventricular extrasystole (≤10/hour)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>These patients will undergo at the inclusion and 36 months after the inclusion :&#xD;
According to recommendations : echocardiography, 24-hour external loop recording and exercise ECG,&#xD;
And specifically for research purposes : injected cardiac MRI and a blood collection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A (b) : patients without mitral regurgitation with ventricular extrasystole (&gt;10/hour)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>These patients will undergo at the inclusion and 36 months after the inclusion :&#xD;
According to recommendations : echocardiography, 24-hour external loop recording, exercise ECG, injected cardiac MRI,&#xD;
And specifically for research purposes : prolongation of the MRI examination (4D flow sequence) and a blood collection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B : patients with Mitral valve prolapse with trivial mitral regurgitation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>These patients will undergo at the inclusion and 36 months after the inclusion :&#xD;
According to recommendations : echocardiography, 24-hour external loop recording, exercise ECG, injected cardiac MRI,&#xD;
And specifically for research purposes : prolongation of the MRI examination (4D flow sequence) and a blood collection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C : patients with Mitral valve prolapse with moderate or mild mitral regurgitation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>These patients will undergo at the inclusion and 36 months after the inclusion :&#xD;
According to recommendations : echocardiography, 24-hour external loop recording, exercise ECG, injected cardiac MRI,&#xD;
And specifically for research purposes : prolongation of the MRI examination (4D flow sequence) and a blood collection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cardiac MRI</intervention_name>
    <description>Injected cardiac MRI</description>
    <arm_group_label>Group A (a) : patients without mitral regurgitation without ventricular extrasystole (≤10/hour)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood collection</intervention_name>
    <description>Blood collection (including genetics at the inclusion visit)</description>
    <arm_group_label>Group A (a) : patients without mitral regurgitation without ventricular extrasystole (≤10/hour)</arm_group_label>
    <arm_group_label>Group A (b) : patients without mitral regurgitation with ventricular extrasystole (&gt;10/hour)</arm_group_label>
    <arm_group_label>Group B : patients with Mitral valve prolapse with trivial mitral regurgitation</arm_group_label>
    <arm_group_label>Group C : patients with Mitral valve prolapse with moderate or mild mitral regurgitation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Prolongation of the MRI examination</intervention_name>
    <description>Prolongation of the MRI examination (4D flow sequence ; about 10 min)</description>
    <arm_group_label>Group A (b) : patients without mitral regurgitation with ventricular extrasystole (&gt;10/hour)</arm_group_label>
    <arm_group_label>Group B : patients with Mitral valve prolapse with trivial mitral regurgitation</arm_group_label>
    <arm_group_label>Group C : patients with Mitral valve prolapse with moderate or mild mitral regurgitation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient over 18 years old,&#xD;
&#xD;
          -  Patient with mitral valve prolapse,&#xD;
&#xD;
          -  Patient who has received full information about the organization of the research and&#xD;
             has signed an informed consent,&#xD;
&#xD;
          -  Patient affiliated to or beneficiary of a social security insurance,&#xD;
&#xD;
          -  Patient who has completed a prior clinical examination adapted to the research and who&#xD;
             does not show any contraindication to the planned examinations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Stage of the disease: Patients with MVP with severe mitral regurgitation with a&#xD;
             surgical indication as defined by current recommendations will not be included in the&#xD;
             study,&#xD;
&#xD;
          -  Presence of severe rhythm disorders requiring the implantation of a defibrillator&#xD;
             (cardiorespiratory arrest recovered, sudden death recovered, etc.),&#xD;
&#xD;
          -  Performance of an injected MRI in the month preceding the MRI scheduled during visit&#xD;
             n°1,&#xD;
&#xD;
          -  Previously diagnosed cardiopathy that may be responsible for myocardial damage&#xD;
             (ventricular remodeling, alteration of left ventricular systolic function, fibrosis,&#xD;
             etc.) and that may disrupt the interpretation of results (infarction, amyloidosis,&#xD;
             systemic scleroderma, significant aortic valvulopathy, etc.).&#xD;
&#xD;
          -  Contraindication to MRI examination, particularly in the presence of an implantable&#xD;
             pacemaker or defibrillator, implanted pump, cochlear implants, neurosurgical clips,&#xD;
             intraorbital or encephalic metallic foreign bodies,&#xD;
&#xD;
          -  Claustrophobia or morphotype that does not allow MRI to be performed,&#xD;
&#xD;
          -  Motor or mental disability,&#xD;
&#xD;
          -  Renal impairment that does not allow the injection of Gadolinium-based contrast media&#xD;
             (DOTAREM® or equivalent in the study). If there is any doubt as to the patient's renal&#xD;
             function, a plasma creatinine determination will be performed for MRI to ensure the&#xD;
             absence of renal failure,&#xD;
&#xD;
          -  Hypersensitivity to gadoteric acid, meglumine, or any gadolinium-containing drug.&#xD;
&#xD;
          -  Women of childbearing age who do not have effective contraception,&#xD;
&#xD;
          -  Persons referred to in Articles L. 1121-5 to L1121-8 of the Public Health Code.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nancy University Hospital</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jean-Marc SELLAL, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Olivier HUTTIN, MD</last_name>
      <phone>+33383157355</phone>
      <email>o.huttin@chru-nancy.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 16, 2021</study_first_submitted>
  <study_first_submitted_qc>April 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2021</study_first_posted>
  <last_update_submitted>June 3, 2021</last_update_submitted>
  <last_update_submitted_qc>June 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central Hospital, Nancy, France</investigator_affiliation>
    <investigator_full_name>Dr Jean-Marc SELLAL</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Prolapse</mesh_term>
    <mesh_term>Prolapse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

